DSM Recognized With Profiles in Sustainability Award for Corporate Commitment to Sustainability and Innovations for Pharmaceutical Manufacturing
PARSIPPANY, N.J., Feb. 9, 2011 /PRNewswire/ -- DSM Pharmaceutical Products, the pharmaceutical manufacturing organization within Royal DSM N.V. (DSM KON, Euronext), a global Life Sciences and Materials Sciences company, and #1 on the Dow Jones Sustainability Index 2010, was recognized in the category of "Product, Process and Green Innovations" at InformexUSA, where the award was announced yesterday in Charlotte, North Carolina.
DSM was considered based on its corporate commitment and ongoing innovations in pharmaceutical manufacturing for the sustainable, cost-effective production of active pharmaceutical ingredients and intermediates. In 2010, as part of this continued commitment, DSM launched InnoSyn™ route scouting services in response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes. DSM's route scouting capabilities can lead to significant cost savings and a better environmental footprint by the reduction of synthesis steps or redesign of synthesis routes using "innovative synthesis".
DSM's InnoSyn™ route scouting supports the research and development initiatives of pharmaceutical companies by integrating the full range of DSM competencies such as biocatalysis, homogeneous catalysis, micro reactor technology and other advanced synthesis methods that speed up feasibility studies. DSM's rapid screening and scale-up also provide robust, cost-effective 'next generation' manufacturing solutions important for drug life cycle management focusing on cost reduction. In October 2010, DSM was recognized with a European Outsourcing Award for "Most Improved Process" with the submission of a customer success story entitled, "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate", in which DSM identified a faster, 3-step route with the same reliability and stable quality as the original 7-step process, with a carbon footprint reduction of over 50%.
Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "DSM is committed to continuous innovation to provide ever more-efficient and sustainable alternatives, and we are proud to offer such viable manufacturing solutions for the future of pharmaceuticals. As a manufacturing partner to the pharmaceutical industry, we make a commitment to employ expertise across our organization to achieve success for our unique customer challenges. DSM is driving sustainability for both small and large molecule production. Route scouting is part of DSM's "green chemistry toolbox" which also integrates process intensification activities, such as micro reactor technology, that increase yield and reduce waste for small molecules. And we apply similar concepts in biotechnological manufacturing with our XD® and Rhobust™ technologies that minimize production volumes and process steps, resulting in higher plant utilization and less labor. Additionally, we are employing DSM's microbial fermentation for a range of enzyme production." Luca Mantovani, President and Business Unit Director of DSM Pharma Chemicals, explained, "A large number of complex chemical steps need to take place in traditional pharmaceutical manufacturing. Optimizing first generation and next generation processes by driving down the cost curve is crucial for the commercial success of pharmaceutical compounds – both those new to the market and those being considered for life cycle extension."
DSM also exhibited as part of InformexUSA and gave two presentations on "(Bio)Catalyst screening for faster design of sustainable manufacturing routes" and "Turning Green Chemistry and Sustainability into Business Drivers." The Profiles in Sustainability awards are given by United Business Media Limited, a global business media company and parent of InformexUSA.
InnoSyn™ is a trademark of Royal DSM N.V.
DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com
DSM Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and Tunitas Therapeutics Sign Agreement to Develop Lead Allergy Therapeutic
Dec 03, 2013, 11:00 ET
DSM and Opthea Sign Agreement to Manufacture Opthea's Lead Product for Eye Disease
Oct 29, 2013, 17:55 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.